{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:51:43Z","timestamp":1791118303326,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T00:00:00Z","timestamp":1256774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T00:00:00Z","timestamp":1256774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/jhh.2009.81","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T10:22:34Z","timestamp":1256811754000},"page":"387-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension"],"prefix":"10.1038","volume":"24","author":[{"given":"A","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,29]]},"reference":[{"key":"BFjhh200981_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/10641969709083193","volume":"19","author":"JW Funder","year":"1997","unstructured":"Funder JW . Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997; 19: 885\u2013899.","journal-title":"Clin Exp Hypertens"},{"key":"BFjhh200981_CR2","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M Young","year":"1994","unstructured":"Young M, Fullerton M, Dilley R, Funder JW . Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578\u20132583.","journal-title":"J Clin Invest"},{"key":"BFjhh200981_CR3","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT . Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992; 120: 893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"BFjhh200981_CR4","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier Jr CT, Kifor I, Ochoa-maya MR, Rennke HG, Williams GH et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871\u20133878.","journal-title":"Endocrinology"},{"key":"BFjhh200981_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1291\/hypres.27.303","volume":"27","author":"A Sato","year":"2004","unstructured":"Sato A, Saruta T . Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303\u2013310.","journal-title":"Hypertens Res"},{"key":"BFjhh200981_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709\u2013717.","journal-title":"N Engl J Med"},{"key":"BFjhh200981_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309\u20131321.","journal-title":"N Engl J Med"},{"key":"BFjhh200981_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T . Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64\u201368.","journal-title":"Hypertension"},{"key":"BFjhh200981_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T . Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44\u201349.","journal-title":"Am J Hypertens"},{"key":"BFjhh200981_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/106002809002400112","volume":"24","author":"HA Skluth","year":"1990","unstructured":"Skluth HA, Gums JG . Spironolactone: a re-examination. DICP 1990; 24: 52\u201359.","journal-title":"DICP"},{"key":"BFjhh200981_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA . Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925\u2013930.","journal-title":"Am J Hypertens"},{"key":"BFjhh200981_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839\u2013845.","journal-title":"Hypertension"},{"key":"BFjhh200981_CR13","first-page":"38","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W . Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Hypertens 2003; 92: 38\u201342.","journal-title":"Am J Hypertens"},{"key":"BFjhh200981_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990\u2013996.","journal-title":"Am J Cardiol"},{"key":"BFjhh200981_CR15","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148\u20131155.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh200981_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426\u2013433.","journal-title":"Am Heart J"},{"key":"BFjhh200981_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021\u20131026.","journal-title":"Hypertension"},{"key":"BFjhh200981_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ . Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709\u2013716.","journal-title":"Am J Hypertens"},{"key":"BFjhh200981_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, He W, Roniker B, Krause S et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117\u2013123.","journal-title":"Hypertension"},{"key":"BFjhh200981_CR20","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","volume":"25","author":"ED Burgess","year":"2003","unstructured":"Burgess ED, Lacourciere Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003; 25: 2388\u20132404.","journal-title":"Clin Ther"},{"key":"BFjhh200981_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers A, Krum H, Williams GH . A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153\u2013158.","journal-title":"Clin Cardiol"},{"key":"BFjhh200981_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","volume":"6","author":"T Saruta","year":"2004","unstructured":"Saruta T, Kageyama S, Ogihara T, Hiwata K, Ogawa M, Tawara K et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-control, dose-ranging study. J Clin Hypertens 2004; 6: 175\u2013183.","journal-title":"J Clin Hypertens"},{"key":"BFjhh200981_CR23","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"DG Levy","year":"2004","unstructured":"Levy DG, Rocha R, Funder JW . Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736\u20132740.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFjhh200981_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/HJH.0b013e328013f492","volume":"25","author":"U Hillebrand","year":"2007","unstructured":"Hillebrand U, Schillers H, Riethmuller C, Stock C, Wilhelmi M, Oberleithner H et al. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J Hypertens 2007; 25: 639\u2013647.","journal-title":"J Hypertens"},{"key":"BFjhh200981_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.107.093450","volume":"50","author":"CL Sartorio","year":"2007","unstructured":"Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007; 50: 919\u2013925.","journal-title":"Hypertension"},{"key":"BFjhh200981_CR26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1177\/0091270003258189","volume":"43","author":"LM Prisant","year":"2003","unstructured":"Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W . Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003; 43: 1203\u20131210.","journal-title":"J Clin Pharmacol"},{"key":"BFjhh200981_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/hr.2008.4","volume":"32","author":"The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension","year":"2009","unstructured":"The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Chapter 4. Lifestyle modification. Hypertens Res 2009; 32: 29\u201332.","journal-title":"Hypertens Res"},{"key":"BFjhh200981_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00129784-200505010-00007","volume":"5","author":"KF Croom","year":"2005","unstructured":"Croom KF, Perry CM . Eplerenone. A review of its use in essential hypertension. Am J Cardiovasc Drugs 2005; 5: 51\u201369.","journal-title":"Am J Cardiovasc Drugs"},{"key":"BFjhh200981_CR29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFjhh200981_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2174\/1389557054553811","volume":"5","author":"X Hu","year":"2005","unstructured":"Hu X, Li S, McMahon EG, Lala DS, Rudolph AE . Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005; 5: 709\u2013718.","journal-title":"Mini Rev Med Chem"},{"key":"BFjhh200981_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","volume":"163","author":"NK Hollenberg","year":"2003","unstructured":"Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL . Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003; 163: 1543\u20131548.","journal-title":"Arch Intern Med"},{"key":"BFjhh200981_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1291\/hypres.29.211","volume":"29","author":"A Sato","year":"2006","unstructured":"Sato A, Saruta T, Funder JW . Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211\u2013216.","journal-title":"Hypertens Res"},{"key":"BFjhh200981_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","volume":"49","author":"S Kidambi","year":"2007","unstructured":"Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ et al. Association of adrenal steroid with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49: 704\u2013711.","journal-title":"Hypertension"},{"key":"BFjhh200981_CR34","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc07-0525","volume":"30","author":"G Colussi","year":"2007","unstructured":"Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA . Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30: 2349\u20132354.","journal-title":"Diabetes Care"},{"key":"BFjhh200981_CR35","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endcrinol Metab 2006; 91: 3457\u20133463.","journal-title":"J Clin Endcrinol Metab"},{"key":"BFjhh200981_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, Sonino N, Mea PD, Ermani M et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endcrinol Metab 2006; 91: 454\u2013459.","journal-title":"J Clin Endcrinol Metab"},{"key":"BFjhh200981_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3109\/07435809809032689","volume":"24","author":"TL Goodfriend","year":"1998","unstructured":"Goodfriend TL, Egan BM, Kelley DE . Aldosterone in obesity. Endcrine Res 1998; 24: 789\u2013796.","journal-title":"Endcrine Res"},{"key":"BFjhh200981_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1210\/endo-100-2-398","volume":"100","author":"D Feldman","year":"1977","unstructured":"Feldman D, Loose D . Glucocorticoid receptors and adipose tissue. Endocrinology 1977; 100: 398\u2013405.","journal-title":"Endocrinology"},{"key":"BFjhh200981_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0303-7207(03)00094-7","volume":"203","author":"DJ Morris","year":"2003","unstructured":"Morris DJ, Brem AS, Ge R, Jellinck PH, Sakai RR, Hardy MP . The functional roles of 11\u03b2-HSD1: vascular tissue, testis and brain. Mol Cell Endocrinol 2003; 203: 1\u201312.","journal-title":"Mol Cell Endocrinol"},{"key":"BFjhh200981_CR40","first-page":"1","volume":"56","author":"PM Stewart","year":"2001","unstructured":"Stewart PM, Toogood AA, Tomlinson JW . Growth hormone, insulin-like growth factor-1 and cortisol-cortisone shuttle. Horm Res 2001; 56: 1\u20136.","journal-title":"Horm Res"},{"key":"BFjhh200981_CR41","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1210\/me.2005-0089","volume":"19","author":"LPL Tallec","year":"2005","unstructured":"Tallec LPL, Lombes M . The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endcrinol 2005; 19: 2211\u20132221.","journal-title":"Mol Endcrinol"},{"key":"BFjhh200981_CR42","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1096\/fj.06-7970com","volume":"21","author":"M Caprio","year":"2007","unstructured":"Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC . Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185\u20132194.","journal-title":"FASEB J"},{"key":"BFjhh200981_CR43","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1291\/hypres.30.1077","volume":"30","author":"Y Ohta","year":"2007","unstructured":"Ohta Y, Tsuchihashi T, Arakawa K, Onaka U, Ueno M . Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an out-patients clinic in Fukuoka, Japan. Hypertens Res 2007; 30: 1077\u20131082.","journal-title":"Hypertens Res"},{"key":"BFjhh200981_CR44","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1093\/ndt\/gfm409","volume":"22","author":"T Fujita","year":"2007","unstructured":"Fujita T . Insulin resistance and salt-sensitive hypertension in metabolic syndrome. Nephrol Dial Transplant 2007; 22: 3102\u20133107.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh200981.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh200981","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh200981.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T23:51:40Z","timestamp":1739404300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh200981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,29]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFjhh200981"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2009.81","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,29]]},"assertion":[{"value":"26 June 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}